2265 Upper Middle Road East
Oakville, ON L6H 0G5
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees:
|Mr. David G. Elsley M.B.A., MBA||Pres, CEO & Director||623.76k||N/A||N/A|
|Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, M.B.A., MBA||CFO, Corp. Sec. & Director||239.67k||N/A||N/A|
|Mr. Bernard Lim B.Sc.||Chief Operating Officer||308.35k||N/A||N/A|
|Dr. Andrew Warwick Hamer M.D.||Chief Medical Officer & Head of R&D||360.04k||N/A||1962|
|Trevor Burns||Investor Relations||N/A||N/A||N/A|
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Cardiol Therapeutics Inc.’s ISS Governance QualityScore as of February 1, 2023 is 7. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 3; Compensation: 9.